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Abstract 
 
 
Aims: Flavanol-rich chocolate (FRC) is beneficial for vascular and platelet function 
by increasing nitric oxide bioavailability and decreasing oxidative stress. Congestive 
heart failure (CHF) is characterized by impaired endothelial and increased platelet 
reactivity. As statins are ineffective in CHF, alternative therapies are a clinical need. 
We therefore investigated whether FRC might improve cardiovascular function in 
patients with CHF. 
Methods and Results: Twenty patients with CHF were enrolled in a double-blind, 
randomized placebo-controlled trial, comparing the effect of commercially available 
FRC with cocoa-liquor free control chocolate (CC) on endothelial and platelet 
function in the short-term (2hours after ingestion of a chocolate bar) and long-term 
(4weeks, two chocolate bars/day). Endothelial function was assessed non-invasively 
by flow-mediated vasodilatation (FMD) of the brachial artery. FMD significantly 
improved from 4.98±1.95% to 5.98±2.32% (p=0.045; p=0.02 for between group 
changes) two hours after intake of FRC, and to 6.86±1.76% after four weeks of daily 
intake (p=0.03; p=0.004 between groups). No effect on endothelial-independent 
vasodilation was observed. Platelet adhesion significantly decreased from 3.9±1.3% 
to 3.0±1.3% (p=0.03; p=0.05 between groups) 2 hours after FRC, an effect that was 
not sustained at two and four weeks. Cocoa-liquor free CC had no effect, either on 
endothelial or platelet function. Blood pressure and heart rate did not change in either 
group. 
Conclusion: FRC acutely improves vascular function in patients with CHF. A 
sustained effect was seen after daily consumption over a 4 weeks period, even after 
12 hours abstinence. These beneficial effects were paralleled by an inhibition of 
platelet function in the presence of FRC only. 
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Introduction 
         Cocoa consumption exerts several beneficial effects on cardiovascular 
health.1 Epidemiologically, its consumption is inversely correlated with blood 
pressure and all cause mortality,2 which has been recently confirmed in a large 
population based study.3 However, there are no large scale prospective morbidity 
and mortality trials evaluating the effect of cocoa so far, but smaller randomized 
studies convincingly proved beneficial short term effects on cardiovascular 
surrogates, namely on endothelial function.1 Endothelial dysfunction is a 
pathophysiologic condition, associated with premature atherothrombotic disease.4 
Diminished NO bioavailability and increased oxidative stress are among the most 
important features of endothelial dysfunction.5 Endothelial function can be assessed 
non-invasively by ultrasound guided measuring of flow-mediated vasodilatation 
(FMD) of the brachial artery. It correlates with coronary endothelial function and is 
predictive of future coronary events.6-8  
Congestive heart failure (CHF) is a prevalent condition, representing the final 
stage of most cardiovascular diseases and is associated with high morbidity and 
mortality.9 Patients with CHF typically show endothelial dysfunction, increased 
oxidative stress, and baroreceptor dysfunction.10 Moreover, patients with impaired 
FMD, are at increased risk for cardiovascular events and death10 complications of 
atherosclerosis that involve increased platelet activation. Indeed, many complications 
in heart failure are thrombus related and increased platelet activation has been 
observed in CHF.11 
Cocoa acutely improve NO-dependent vasodilatation in healthy humans12 and 
in patients with cardiovascular risk factors, including diabetes, both in the forearm 
circulation13-15 as well as in coronary arteries.16 CHF is a very late stage of most 
Effect of cocoa on vascular health in patients with CHF   
 
 5
forms of cardiovascular disease. At that stage many cardiovascular alterations are 
irreversible. For instance, lowering of low-density lipoproteins by HMG coenzyme 
reductase inhibitors does not longer reduce the event rates even in patients with 
ischemic cardiomyopathy.17, 18 Thus, alternative treatment options have to be 
explored in these high risk patients. Due to its potential to enhance NO bioavailability 
and its antioxidative properties, flavanol-rich chocolate (FRC) might be beneficial in 
CHF patients. It was thus the aim of this double-blind, placebo-controlled study to 
evaluate both the acute (2 hours after ingestion), as well as the longer-term (at 2 and 
4 weeks) effects of FRC as compared to a cocoa-liquor-free CC on endothelial and 
platelet function in patients with CHF.  
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METHODS 
Subjects  
22 patients with stable CHF (NYHA≥II) and ejection fraction<50% have been 
randomized. Exclusion criteria were: Decompensated HF, unstable angina pectoris, 
smoking, creatinine>200 µmol/L, ALT or AST>150 IU, diabetes mellitus, obesity 
(BMI>30 kg/m2), symptomatic hypotension, BP>160/100mmHg, known allergies to 
compounds of study chocolate or placebo, respectively, history of gastric ulcer or 
bleeding, venous thrombosis or pulmonary embolism, history of infectious disease or 
systemic inflammatory diseases, malignant tumors (unless cured or in remission for 
more than 5 years), concomitant vitamin supplements as well as participation in 
another study within the last month. Two patients dropped out during follow-up (one 
patient withdrew consent because of personal reasons, one patient was excluded 
due to ventricular fibrillation, terminated by an internal defibrillator; this event was 
considered unrelated to the study protocol). 20 patients were included into the final 
analysis.  
Flavanol-rich as well a control chocolate (CC) were prepared by Nestlé. Both 
were wrapped identically and randomization was done by an organization 
independent of the study group (InterCorNet, Zürich, Switzerland).  
 All patients gave signed informed consent. The study was performed at the 
University Hospital of Zurich, and the study protocol approved by the local ethics 
committee and conducted according to the Declaration of Helsinki. Patients were 
recruited from the heart failure outpatient clinic. 
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Experimental Protocol  
All patients were instructed to refrain from flavanol-rich food for 24 hours and 
fast for at least 8 hours before baseline examinations, which were always performed 
in the morning. After a short clinical examination and blood sampling, baseline 
measurements were performed. Blood pressure was measured 3 times with a 
validated automatic BP device (OMRON Mit Elite Plus). The mean of the last 2 
measurements was recorded. Following the first assessment, the participants were 
randomized to receive either 40g of FRC or 28.4g CC (weight matched for fat and 
sugar content to the dark chocolate), which had to be ingested within 10 minutes. A 
nurse not directly involved in the study distributed study chocolate to the patient.  
The study design is summarized in Figure 1. Primary endpoint of the study 
was endothelial function measured as flow mediated dilatation of the brachial artery. 
Secondary endpoints were baroreceptor function, platelet adhesion and oxidative 
stress parameters. To assess the short-term effects, two hours after the baseline 
visit, endothelial, as well as baroreceptor-function and platelet adhesion 
measurements were repeated. Afterwards, all participants obtained a box with 
blinded FRC or CC bars, respectively, and were instructed to ingest one bar twice a 
day and to continue their normal daily diet. Endothelial function, platelet and 
baroreceptor function were reassessed at 2 and 4 weeks to assess the longer-term 
effect. Measurements were performed after overnight fasting (at least 8 hours) to 
assess thoroughly the long-term effects. 
 
Study chocolate and control 
The FRC bars consisted of a commercially available preparation (Nestlé Noir 
IntenseTM). This chocolate contains 10.5g sugar and 17.9g of fat per 40g serving with 
70% cocoa content. The catechin and epicatechin concentrations were 0.27mg/g and 
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0.9mg/g, respectively (as measured by high performance liquid chromatography), 
with total polyphenol content (as measured by the Folin-Ciocalteau method) of 
15.6mg epicatechin equivalents/g (data from Nestlé Research Center, Lausanne, 
Switzerland). Nestlé also supplied the cocoa-liquor-free chocolate CC, given in 28.4g 
portions to match carbohydrate and fat content to 40g dark chocolate.  The chocolate 
bars were identically wrapped to avoid any potential bias for the patient or 
examinators. 
 
Flow mediated vasodilatation 
Endothelial function was assessed by measurement of the FMD of the brachial 
artery as described previously.7, 19 In brief, while patients were in supine position, at 
rest, in a quiet air conditioned room a two-dimensional scan of the left brachial artery 
was obtained in a longitudinal section between 2 and 10 cm above the elbow, using a 
high-resolution 10Mhz linear array transducer and a high-resolution ultrasound 
system (Siemens Acuson X300). The transducer was kept in the same position 
during examination with the help of a stereotactic clamp to ensure consistency of the 
image. The analog video signal was acquired with a video processing system, which 
computes the artery diameter in real-time (FMD Studio,Pisa, Italy).20 
One minute after acquisition of the basal diameter a wrist cuff was inflated to 
220mmHg for 5 minutes. Immediately after release, arterial diameter was 
continuously recorded during reactive hyperemia and flow velocity was measured.  
Baseline vessel size was considered as the mean of the measures obtained during 
the first minute. FMD was calculated as the maximal percent increase in diameter 
above the baseline. Endothelial-independent dilation was measured after glyceryl 
trinitrate (0.4 mg sublingual, Pohl-Boskamp, Germany) sublingual application by 
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recording arterial diameter continuously. The reproducibility of our laboratory has 
been previously published.21 
 
Shear Stress-Dependent Platelet adhesion 
Shear stress dependent platelet adhesion was assessed using the cone and 
platelet analyzer. In brief, citrated whole blood (200 µl) was circulated in polystyrene 
wells at a shear rate of 1875 s-1 for 2 minutes with a rotating Teflon cone, as 
described previously.22 Wells were washed, stained with May-Grünwald, and 
analyzed with a microscope connected to an image analysis system. Results were 
expressed as the percentage surface covered by platelets and as the size of the 
platelet aggregates (ImageJ 1.31, National Institute of Health, USA). 
 
Baroreflex function 
Heart rate was measured together with blood pressure using an ECG and 
Dynamap (Critikon, Inc, Tampa, Florida) respectively. Data were stored and analyzed 
off-line with MatLab (The Math Works, Inc., Natrick, Massachusetts). The 
assessment of baroreceptor function was done off-line with the alpha-coefficient 
method as previously described.23 Due to technical reasons, these data were 
available in 11 patients only (6 in the group receiving flavanol-rich chocolate and 5 in 
the control group). 
 
Biomarkers of oxidative stress 
Serum samples were analyzed at the Antioxidant Research Laboratory of the 
Unit of Human Nutrition INRAN in Rome, Italy and the analyses were performed 
before unblinding of the study. The TRAP (total radical-reducing antioxidant potential) 
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method is based on the protection provided by antioxidants against the fluorescence 
decay of R-phycoerythrin (lag phase) during a controlled peroxidation reaction.  
The FRAP (ferric-reducing antioxidant potential) assay is based on reduction 
of the Fe3+-TPTZ complex to the ferrous form at low pH monitored at 595 nm by a 
Sunrise absorbance plate reader (Tecan Italia).  
Total 8-iso-prostaglandin F2α (8-iso-PGF2α) was quantified in serum samples 
with a direct 8-iso-PGF2α enzyme immunoassay kit (Assay Designs Inc, Ann Arbor, 
Mich). All 3 tests have been described in detail earlier.16 
 
Assessment of plasma flavanol concentrations 
The plasma samples were sent to the Nestlé Research Centre, Lausanne, 
Switzerland, where the analyses were performed. The bioavailability of flavanols was 
assessed by identifying (-)-epicatechin, 3’-O-methyl-epicatechin, 4’-O-methyl-
epicatechin and procyanidin B2 in plasma samples using a Waters Acquity Ultra-
PerformanceTM liquid chromatography system (Waters, Baden, Switzerland) with 
fluorimetric detection. Prior to the chromatographic analysis, the plasma samples 
were treated by off-line SPE according to the method described by Unno et al.24 with 
some modification. 
The limits of quantification for (-)-epicatechin, 3’-O-methyl-epicatechin, 4’-O-
methyl-epicatechin and procyanidin B2 in plasma samples were 100, 25, 25, 50 nM 
respectively. The overall recovery tested at three different concentrations was 84%; 
93%; 94%; 78% for (-)-epicatechin, 3’-O-methyl-epicatechin, 4’-O-methyl-epicatechin 
and procyanidin B2, respectively. 
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Statistical analysis 
The change in flow mediated vasodilation was defined as primary endpoint. 
The power calculation was based upon results of earlier studies in our laboratory. An 
FMD delta of 1.5%, and standard deviation of 1.5% for FRC versus control at 4 
weeks was hypothesized. For a significance level of 5%, 10 patients per treatment 
group were assumed to be needed to reach a statistical power of 80%. The data was 
checked for normal distribution and most data was considered normally distributed. 
Therefore data was expressed as mean ± standard deviation. To assess intra- as 
well as intergroup changes for FMD at any time points, the Wilcoxon-test was used. 
Additionally, we computed an analysis of covariance (ANCOVA) to assess the effect 
of treatment while correcting for the baseline values. The rest of the data were 
analyzed by paired and unpaired Student t-Test, and the Wilcoxon-Test as 
appropriate. All tests were two-sided and analysis was per protocol.  A p-value of 
less than 0.05 was considered statistically significant. Statistics were performed 
using SPSS 17 for Mac OS X.  
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RESULTS 
Clinical characteristics 
Baseline characteristics and medications of the study population are shown in Table 
1. No significant difference was found between the two groups with the exception of a 
slightly lower plasma potassium in the group assigned to FRC (4.0±0.2 and 4.2±0.3, 
p=0.05, respectively). Risk factor distribution was similar between the groups: history 
of arterial hypertension (FRC 2 out of 10 and CC 3 out of 10, respectively), 
dyslipidemia (FRC 7/10, CC 5/10) and positive family history for cardiovascular 
disease (FRC 7/10, CC 6/10). According to the protocol, patients with diabetes 
mellitus and smokers were not included. Patients remained clinically stable during 
the study with no heart failure decompensation noted as also reflected by unchanged 
proBNP levels (from 898.6±1084.7 to 743.5±1059.3ng/l after FRC and from 
667.0±443.5 to 684.5±513.7ng/l after CC, respectively). Weight remained stable 
during the 4 weeks course of daily chocolate ingestion (76.7±18.8 to 76.9±18.7kg 
and 76.8±11.6 to 77.3±11.4kg, respectively).  
 
Blood Pressure and Heart Rate 
Systolic, as well as diastolic BP and heart rate were not affected in the short-, 
as well as in the longer-term (Table 2 and 3). HR was rather low in this patient 
group, reflecting the appropriate use of beta-blockers in this population.  
 
Laboratory Parameters 
In the group receiving cocoa-liquor-free chocolate there was a significant 
decrease in insulin-sensitivity as assessed by the quantitative insulin sensitivity 
check index (QUICKI, Table 1 and 3), interestingly, an effect not seen in the FRC-
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group. Otherwise, both FRC and cocoa-liquor-free CC had no immediate or longer-
term effects on laboratory parameters. There has been no acute or chronic impact on 
inflammatory as well as on oxidative stress markers, including total antioxidative 
capacity, ferric reducing antioxidative capacity or isoprostanes (Table 2 and 3).  
The slight but statistically nonsignificant higher plasma levels of hsCRP in the control 
group throughout the study can be attributed to one patient with elevated CRP levels. 
However, exclusion of this particular patient had no significant influence on the 
primary outcome. 
 
Polyphenol Plasma Levels 
There was a significant increase in plasma polyphenols after ingestion of FRC, 
as compared to cocoa-liquor-free CC. Epicatechin concentration increased (from 
below detection limit to 0.69±0.28 µM, p<0.001 for intra- and between group 
changes), whereas no plasma epicatechin were detectable before and after CC. 
However, in the FRC group (-)-epicatechin metabolites were only detected in the 
short term (2 h after ingestion) but not at the end of the 4-week treatment period (12 
h after the last ingestion) (Table 2).  
 
Flow-mediated Dilatation of the Brachial Artery 
Baseline brachial artery diameter and baseline FMD were similar in both 
groups. Two hours after ingestion of 40 g FRC FMD increased from 4.98±1.95% to 
5.98±2.32% (p=0.045, p=0.02 between-groups), whereas the 28.4g CC showed no 
effect (from 5.06±2.29% to 4.47±1.5%; p=0.44). Similarly, chronic daily intake of 80g 
of FRC resulted in a significant amelioration of endothelial dysfunction both after two 
(from 4.98±1.95% to 5.82±1.54%; p=0.045, p=0.33 between-groups), as well as after 
four weeks (from 4.98±1.95% to 6.86±1.76%; p=0.027 and p=0.004 between-
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groups), despite a 12 hour refrain from flavanol-rich food before the follow-up 
measurements of FMD. Again, CC did not change FMD over the entire time course 
of up to 4 weeks (Figure 2). In the ANCOVA model to assess the effect of FRC while 
correcting for the baseline FMD values, the between group comparison after 4 weeks 
is even more pronounced (p<0.0001) Nitroglycerin-induced endothelial-independent 
vasodilatation was not different between the groups at all time (see Table 2 and 3); 
additionally, reactive hyperemia was not different between visits or within the 
treatment groups (data not shown). In addition to the improvement in endothelial 
function, FRC significantly increased baseline brachial artery diameter 2 hours after 
ingestion (from 5.2±1.2mm to 5.4±1.1mm; p=0.001, p= 0.01 between groups), while 
in the control group baseline diameter did not change (from 5.4±0.8mm to 
5.4±0.8mm respectively; p=0.10). 
 
Baroreceptor Function 
FRC as well as cocoa-liquor-free CC did not significantly influence 
baroreceptor function in patients with heart failure. There were no acute and chronic 
changes in both, baroreceptor sensitivity in the high and low frequency ranges (Table 
2 and Table 3). 
 
Platelet Function 
FRC intake acutely improved platelet function. Two hours after chocolate 
intake, platelet adhesion was significantly reduced from 3.9±1.3% to 3.0±1.3% 
(p=0.03 and p= 0.05 between groups), whereas no change could be observed in the 
control group (from 3.3±1.9% to 3.5±1.7%, respectively; Figure 3). However, no 
significant effect of FRC on platelet adhesion was found at 4 weeks after chronic 
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ingestion of FRC after a 12-hour refrain period from flavanol-rich food (from 3.9±1.3% 
to 4.1±1.5%, p=0.70 and p=0.43 for between groups, Table 3). 
 
 
DISCUSSION 
 
In the present study we, for the first time, report a significant and specific effect 
of commercially available FRC on endothelial and platelet function, in patients with 
CHF. Interestingly, chocolate not only improved this important cardiovascular 
surrogate marker acutely, but even more so, after longer-term ingestion for up to four 
weeks. Such a vascular positive effect of an orally available molecule is not trivial in 
CHF as unexpectedly statins proved to be ineffective in this patient population.17, 18  
While most studies, so far, investigated only the acute effects of FRC on 
endothelial function,1 we here report long-term effects with daily ingestion of FRC 
using a double-blind randomized design, rarely applied in nutritional research. In 
addition, this is the first study on the effect of chocolate in patients with advanced 
heart disease such as CHF. Of note, CHF is associated with endothelial dysfunction, 
a condition confirmed in our patient population. Indeed, FMD averaged about 4%, 
which is markedly lower than that observed in healthy controls.25 The molecular 
mechanisms of endothelial dysfunction in CHF might involve increased levels of 
cytokines, impaired endothelial-receptor-signal transduction pathways and increased 
angiotensin-converting enzyme activity.26-29 Furthermore, neurohumoral activation 
and increased levels of endothelium-derived vasoconstrictors occurs in CHF.30 In 
addition, CHF is associated with enhanced generation of ROS and oxidized LDL, 
further counteracting vasodilator properties of NO. Therefore, the fact that cocoa 
polyphenols improve endothelial function by increasing NO synthase activity and by 
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exerting antioxidative capacity might be of importance for heart failure patients, 
especially as there is a strong association between endothelial dysfunction and 
cardiovascular morbidity and mortality in these patients.10 Finally, CHF patients, 
particularly at advanced stages, are prone to weight loss, anemia and cachexia, 
making nutritional issues important in the management of such patients. 
 In our study, ingestion of FRC was followed by a marked and significant 
increase in (-)-epicatechin plasma concentrations. In parallel, FMD improved 
significantly in the flavanol, but not in the control group. This effect likely involves 
increased NO bioavailability, since it is reduced in CHF,31 and ingestion of cocoa high 
in flavanols rapidly enhances the pool of bioactive NO and improves FMD in patients 
with hypertension or diabetes.15, 32 Furthermore, after the infusion of L-NMMA, an 
inhibitor of the NO synthesis, the increase in plasma NO levels as well as the 
amelioration of endothelial dysfunction associated with cocoa are blunted.32 
Moreover, a diet high in flavanols has been associated with a high urinary excretion 
of NO metabolites33  and purified (-)-epicatechin has been shown to mimic the 
endothelial effects of flavanol-rich cocoa.33 In the short term, flavanols inhibit the 
inactivation of NO by free radicals via inhibition of NADPH oxidase, while in the long 
term they seem to be able to express higher levels of protein eNOS.34 Furthermore, 
pure (-)-epicatechin ingestion not only augments NO bioavailability, but also reduces 
the plasma levels of endothelin-1, a potent endothelium-derived vasoconstrictor.35  
Besides their effects on endothelial NOS expression, cocoa flavanols also 
exert antioxidant effects in vitro, which could contribute to the results of our study. In 
humans, it has been shown that cocoa is able to counteract lipid peroxidation and 
thus lowering the levels of plasma F2-Isoprostanes, important markers of in vivo lipid 
peroxidation,36 as well as plasma levels of oxLDL,37, and increases overall 
antioxidant capacity.38 Although not obvious in the current study, we showed that in 
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young healthy smokers the same commercially available chocolate as used in the 
present study, was able not only to improve endothelial function but also to improve 
antioxidant status.39 We also evaluated the effect of the same commercially available 
chocolate on cardiac transplant recipients, where we demonstrated a reduction in 
oxidative stress, as assessed by plasma isoprostanes; this was paralleled by 
coronary vasodilatation, improvement in coronary vascular function and decreased 
platelet adhesion.16 
Beyond the acute effects on endothelial function, the sustained and even more 
pronounced effects of chronic cocoa ingestion were remarkable. Indeed, endothelial 
function was further improved after two, and particularly after four weeks of daily 
ingestion of 80g FRC. It is of note that endothelial function measurements were 
performed in the morning after overnight fasting, thus an acute effect of chocolate in 
these measurements can be excluded. Indeed, in line with this assumption, both at 
two weeks and four weeks (-)-epicatechin and its methyl metabolites were no longer 
detectable in plasma at the time of vascular function studies. Therefore, chronic 
flavanol supplementation must have changed the biology of the brachial artery and 
endothelial cells in particular in the CHF patients studied. Although, we do not have a 
mechanistic prove, flavanols most likely must have induced the expression of 
endothelial NOS, an effect that was sustained beyond the short half-life of these 
cocoa-derived nutrients. In line with this interpretation, brachial artery diameter 
increased two hours after ingestion of FRC. Furthermore, plasma levels of oxidative 
stress markers as well as of CRP were similar at two and four weeks as they had 
been at baseline excluding a major contribution of reactive oxidant species. Finally, 
endothelium-independent relaxations to nitroglycerin were unaffected by the dietary 
intervention.  
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 The improvement in platelet function shortly after cocoa ingestion confirms our 
previous studies in young healthy smokers39 and heart transplant recipients.16 
However, we were not able to show any long-term effect after two or four weeks.  
This may be due to the fact that blood samples were collected after an overnight fast 
and thus the polyphenols had already been metabolized and excreted as reflected by 
the lack of detection of these substances in the blood samples. Our findings are not 
surprising, since platelets are anucleated cells and hence unable to induce protein 
production for instance an increased transcription and translation of endothelial NOS 
expression. Hence, it appears that flavanols can activate NO release from platelets 
as previously described,40 but – in contrast to endothelial cells - are unable to exert 
sustained effects in these anucleated cells. 
 Neurohumoral activation, in particular activation of the sympathetic nervous 
system is a hallmark of CHF. Thus, we further investigated the effect of FRC on 
baroreceptor function by the alpha coefficient method. However, no effect of the 
dietary intervention has been noted, neither in the short nor in the long term. This is 
surprising, since NO has been involved in baroreceptor signaling.41 An explanation 
might be the use of beta-blocking agents in all of our patients according to guidelines, 
thus masking a possible effect of FRC. Alternatively, the limited number of 
observations may also contribute to the negative findings, as baroreflex function was 
only measured in 11 patients. 
 Epidemiological and small intervention studies suggest a small, but distinct BP 
lowering effect of chocolate consumption.2, 3, 42, 43 However, these studies were 
performed in patients with elevated or mildly elevated BP. Moreover, the effect of BP 
lowering was higher in subjects with higher baseline BP.43 As it is typical in CHF, 
baseline BP of our patients was low and averaged 110/65 mmHg. We did not 
observe any relevant effect of FRC consumption on systolic or diastolic BP, neither 
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acutely nor after two and four weeks, despite a substantial increase in plasma 
epicatechin levels and that of its metabolites. This might be explained by the low 
baseline BP as well as by the fact that antihypertensive drugs had been used. 
Intervention studies demonstrated improved insulin sensitivity after chocolate 
consumption, especially in hypertensives.14, 42 Interestingly, in this study we observed 
a decrease in insulin sensitivity after 4 weeks in the control group, a decrease not 
seen in patients consuming FRC. This may potentially point towards an additional 
beneficial effect of FRC in CHF patients. It is of note, that despite the high caloric 
load of our commercially available FRC, no weight gain and no change in blood lipids 
were noted.  
There are some limitations of the study. We did not control for habitual food 
intake, especially for other cocoa products. Furthermore, patients were free to 
schedule study chocolate intake thus other foods might have influenced 
bioavailability. Although we think it is unlikely, we cannot exclude that the results are 
biased by the individuals’ diet. We are aware that our results are based on a rather 
small sample size thus effects on secondary endpoints as blood pressure, oxidative 
stress parameters and others might not have been detected.  
 
In conclusion, this is the first study demonstrating beneficial cardiovascular 
effects of commercially available, FRC in patients with CHF. FRC not only led to 
peripheral vasodilatation, improvement in endothelial function and enhancement in 
platelet function shortly after chocolate ingestion but also to an amelioration in 
endothelial function in the long term after two and four weeks of daily chocolate 
ingestion. It is of note that endothelial function was improved on top of optimal 
medical treatment with drugs known to improve vascular function alone.  
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Figure Legends 
 
Figure 1 
Study design. N=actual sample size. 
 
Figure 2  
Effect of flavanol-rich and control chocolate, respectively, on endothelial function 
(measured by flow mediated dilatation - FMD). Two hours after ingestion of flavanol-
rich chocolate, FMD increased from 4.98±1.95% to 5.98±2.32% whereas the control 
chocolate showed no significant effect (from 5.06±2.29% to 4.47±1.5%). Similarly, 
chronic daily intake of 80g of flavonol-rich chocolate resulted in a significant 
amelioration of endothelial dysfunction after four weeks (from 4.98±1.95% to 
6.86±1.76%). *p<0.05. 
 
Figure 3 
Acute Effect of flavanol-rich and control chocolate, respectively, on platelet adhesion. 
p=0.03 for FRC after 2 hours compared to baseline. 
 
 
 
 
 
Effect of cocoa on vascular health in patients with CHF   
 
 25
Tables 
Table 1: Clinical characteristics of the study population (n=20) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Flavanol-rich chocolate (FRC) and control chocolate (CC); FMD: flow-mediated vasodilatation; BMI: body mass 
index; BP: blood pressure; HR: heart rate; Hb: hemoglobin; QUICKI; quantitative insulin sensitivity check index ; 
HDL: high density lipoprotein; LDL: low density lipoprotein; AST: Aspartate Aminotransferase; ALT: Alanin-
Aminotransferase; BNP: B-natriuretic Peptide; hsCRP: high sensitivity C-reactive Protein; ACE: angiotensin 
converting enzyme, ARB: angiotensin receptor blocker.  
 FRC (n=10) CC (n=10) 
Age (years) 60.3±10.1 58.1±11.9 
Male/female 8/2 9/1 
Etiology (ischemic/not ischemic) 5/5 5/5 
Time from CHF diagnosis (years) 6.1±3.9 6.7±5.7 
Ejection Fraction (%) 29.9±9.9 34.7±8.8 
FMD (%) 4.98±1.95 5.06±2.29 
Weight (Kg) 76.7±18.8 76.8±11.6 
BMI (Kg/m2) 25.9±5.1 25.6±3.5 
Systolic BP (mmHg) 109.5±13.0 113.2±18.1 
Diastolic BP (mmHg) 65.8±8.4 68.0±12.3 
HR (b/min) 67.6±11.7 60.1±10.5 
Creatinine (µmol/l) 94.3±11.2 100.6±26.3 
Sodium (mmol/l) 138.0±2.2 139.1±3.3 
Potassium (mmol/l) 4.0±0.2 4.2±0.3 
Hb (g/dl) 14.2±1.0 13.6±1.6 
Platelets (103/mL) 226.5±39.7 231.2±66.9 
Glucose (mmol/l) 6.4±1.1 5.8±1.2 
QUICKI 0.33±0.05 0.33±0.04 
HbA1c (%) 5.9±0.4 5.8±0.4 
Total cholesterol (mmol/l) 4.7±1.1 5.0±1.5 
HDL-cholesterol (mmol/l) 1.2±0.3 1.3±0.3 
LDL-cholesterol (mmol/l) 2.5±1.0 2.9±1.2 
Triglycerides (mmol/l) 2.1±0.9 1.7±0.8 
ALT (U/l) 31.6±7.6 29.6±10.1 
AST (U/l) 42.0±22.4 29.1±10.2 
proBNP (ng/l) 898.6±1084.7 667.0±443.5 
hsCRP  (mg/l) 1.4±1.4 4.4±4.4 
 
Medication 
  
ACE-Inhibitor/ARB 10/10 10/10  
Betablocker 10/10  10/10 
Diuretics 8/10 6/10 
Calcium-Antagonist 1/10  0/10 
Aspirin (100 mg) 4/10 3/10 
Clopidogrel 1/10 2/10 
Statin 7/10 4/10 
Oral anticoagulation 5/10 7/10 
Molsidomin  1/10 1/10 
Digoxin  1/10 3/10 
Antiarrhytmics 0/10 3/10 
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Table 2: Acute Effect (after 2 hours) of flavanol-rich chocolate (FRC) and 
control chocolate (CC) 
 
 * p<0.05 or less vs baseline 
FMD: flow mediated vasodilatation, GTN: Glyceril Trinitrate (Nitroglycerin), SBP: systolic blood pressure, DBP: 
diastolic blood pressure, BRS: baroreceptor sensitivity, LF: low frequency, HF: high frequency, hsCRP: high 
sensitivity C-reactive Protein, TRAP; total reducing antioxidative potential, FRAP: ferric reducing antioxidative 
potential.
 FRC (n=10)             CC (n=10) between 
group p  
 Baseline  +2 hours Baseline + 2 hours  
Diameter (mm) 5.15±1.23 5.41±1.11* 5.43±0.77 5.38±0.76 0.01 
FMD (%) 4.98±1.95 5.98±2.32* 5.06±2.29 4.47±1.5 0.02 
GTN (%) 15.6±5.1 13.1±2.6 13.6±3.1 12.0±3.7 0.48 
Platelet Adhesion (%) 3.87±1.32 2.99±1.31* 3.30±1.86 3.49±1.66 0.05 
SBP (mmHg) 109.5±13.0 112.5±12.9 113.2±18.1 112.3±14.1 0.32 
DBP (mmHg) 65.8±8.4 70.2±9.1 68.0±12.3 69.1±10.3 0.39 
Heart rate (b/min) 67.6±11.7 62.9±7.4 60.1±10.5 60.3±10.9 0.12 
BRS HF (n=6) 27.4±14.4 29.9±19.6 21.0±22.3 21.5±21.7 0.83 
BRS LF (n=5) 16.7±16.3 17.1±13.9 14.9±19.8 22.6±27.2 0.71 
LF/HF (n=5) 1.0±0.6 5.7±13.7 1.0±0.6 1.3±0.7 0.18 
      
Glucose (mmol/l) 6.4±1.1 5.5±0.46* 5.8±1.2 5.1±0.43* 0.07 
hsCRP (mg/l) 1.4±1.4 1.5±1.4 4.4±4.4 4.4±4.4 0.90 
Flavanols (µmol/l) 0.00±0 0.69±0.28* 0.00±0 0.00±0 <0.001 
      
TRAP (µmol/l) 1667±299 1749±297 1599±219 1651±225 0.19 
FRAP (µmol/l) 1412±235 1441±245 1273±173 1325±212 0.78 
8-Isoprostanes(pg/ml) 865.2±228.7 800.3±41.6 831.3±36.9 812.0±38.6 0.46 
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Table 3: Long term Effect (4 weeks) of Flavanol-rich chocolate (FRC) or Control 
Chocolate (CC) 
 
 
 FRC (n=10) CC (n=10) 
 Baseline +4 weeks Baseline +4 weeks 
between 
group p   
 
Brachial artery 
diameter (mm) 
5.15±1.23 5.25±1.22 5.43±0.77 5.28±0.76  
0.02 
FMD (%) 4.98±1.95 6.86±1.76* 5.06±2.29 3.92±1.89 0.004 
GTN (%) 15.6±5.1 13.4±4.2 13.6±3.1 13.7±3.4 0.06 
Platelet Adhesion 
(%) 
3.86±1.32 4.07±1.52 3.30±1.86 3.27±1.77 0.43 
Weight (Kg) 76.7±18.8 76.9±18.7 76.8±11.6 77.3±11.4 0.33 
SBP (mmHg) 109.5±13.0 106.7±7.2 113.2±18.1 117.8±20.5 0.12 
DBP (mmHg) 65.8±8.4 68.1±8.9 68.0±12.3 69.8±8.6 0.87 
Heart rate (b/min) 67.6±11.7 68.3±7.3 60.1±10.5 59.6±11.3 0.71 
BRS HF (n=6) 27.4±14.4 21.2±10.9 21.0±22.3 19.1±9.1 0.53 
BRS LF (n=5) 16.7±16.3 15.4±12.3 14.9±19.8 15.2±18.4 0.40 
LF/HF (n=5) 1.0±0.6 3.3±3.8 1.0±0.6 2.1±2.1 0.31 
      
Creatinine 
(µmol/l) 
94.3±11.2 98.6±17.8 100.6±26.3 103.8±28.6 0.24 
Sodium (mmol/L) 138.0±2.2 138.8±1.0 139.1±3.3 139.0±2.9 0.38 
Potassium 
(mmol/L) 
4.0±0.2 4.0±0.3 4.2±0.3 4.0±0.3 0.07 
      
Glucose (mmol/l) 6.4±1.1 6.4±0.8 5.8±1.2 6.2±1.7 0.13 
QUICKI 0.33±0.05 0.32±0.04 0.33±0.04 0.31±0.05* 0.21 
HbA1c (%) 5.9±0.4 5.8±0.2 5.8±0.4 5.9±0.4 0.15 
ALT (U/L) 31.6±7.6 32.4±7.0 29.6±10.1 28.7±8.9 0.14 
AST (U/L) 42.0±22.4 35.5±14.1 29.1±10.2 30.9±13.5 0.43 
Pro BNP (ng/L) 898.6±1084.7 743.5±1059.3 667.0±443.5 684.5±513.7 0.25 
hsCRP  (mg/l) 1.4±1.4 1.13±1.04 4.4±4.4 4.55±7.1 0.80 
TC (mmol/l) 4.7±1.1 4.8±1.1 5.0±1.5 5.1±1.3 0.91 
HDL-C (mmol/l) 1.2±0.3 1.3±0.26 1.3±0.3 1.3±0.26 0.03 
LDL-C (mmol/l) 2.5±1.0 3.1±0.7 2.9±1.2 2.5±1.2 0.71 
Triglycerides 
(mmol/l) 
2.1±0.9 1.9±1.2 1.7±0.8 1.7±0.43 0.51 
TRAP (µmol/l) 1667±299 1728±259 1599±219 1696±242 0.47 
FRAP (µmol/l) 1412±235 1446±269 1273±173 1331±230 0.79 
8-Isoprostanes 
(pg/ml) 
865.2±228.7 790.7±35.7 831.3±36.9 783.5±46.0 0.52 
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* p<0.05 or less vs baseline 
FMD: flow mediated vasodilatation, GTN: Glyceril Trinitrate (Nitroglycerin), SBP: systolic blood pressure, DBP: 
diastolic blood pressure, BRS: baroreceptor sensitivity, LF: low frequency, HF: high frequency; QUICKI; 
quantitative insulin sensitivity check index; AST: Aspartate Aminotransferase; ALT: Alanin-Aminotransferase; 
BNP: B-natriuretic Peptide;  hsCRP: high sensitivity C-reactive Protein, TC: triglycerides; HDL-C high density 
lipoprotein cholesterol, LDL-C low density lipoprotein cholesterol, TRAP; total reducing antioxidative potential, 
FRAP: ferric reducing antioxidative potential.
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Figure 1 
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Figure 2  
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Figure 3  
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